nach oben

Erschienen in:

11.03.2022 | Schwerpunkt

Prävention des plötzlichen Herztods

verfasst von: Alireza Sepehri Shamloo, MD, Patrick Dilk, Nikolaos Dagres

Erschienen in: Herz | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der plötzliche Herztod (PHT) stellt ein sehr großes, bisher ungelöstes Problem der öffentlichen Gesundheit dar. Die Prävention des PHT wird in 2 Hauptkategorien unterteilt, und zwar zum einen in die Primär- (Prävention eines ersten Ereignisses von PHT) und zum anderen in die Sekundärprävention (Prävention von Wiederholungsereignissen bei Überlebenden eines Herzstillstands). In diesem Übersichtsartikel wird der aktuelle Wissensstand über die Primär- und Sekundärprävention des PHT in verschiedenen klinischen Situationen zusammengefasst.

Priori SG, Blomström-Lundqvist C, Mazzanti A et al (2016) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Rev Esp Cardiol (Engl Ed) 69(2):176. https://doi.org/10.1016/j.rec.2016.01.001CrossRef

Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm 15(10):e190–e252. https://doi.org/10.1016/j.hrthm.2017.10.035PubMedCrossRef

Dagres N, Peek N, Leclercq C, Hindricks G (2020) The PROFID project. Eur Heart J 41(39):3781–3782. https://doi.org/10.1093/eurheartj/ehaa645PubMedPubMedCentralCrossRef

Priori SG, Blomstrom-Lundqvist C (2015) 2015 European society of cardiology guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J 36(41):2757–2759. https://doi.org/10.1093/eurheartj/ehv445PubMedCrossRef

Bob-Manuel T, Jenkins JS, Morin DP (2019) Non-arrhythmic causes of sudden death: a comprehensive review. Prog Cardiovasc Dis 62(3):265–271. https://doi.org/10.1016/j.pcad.2019.05.004PubMedCrossRef

Nogami A, Kurita T, Abe H et al (2021) JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. J Arrhythm 37(4):709–870. https://doi.org/10.1002/joa3.12491PubMedPubMedCentralCrossRef

Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ et al (2020) European heart rhythm association (EHRA)/heart rhythm society (HRS)/asia pacific heart rhythm society (APHRS)/latin American heart rhythm society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace 22(8):1147–1148. https://doi.org/10.1093/europace/euaa065PubMedPubMedCentralCrossRef

McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368CrossRef

Priori SG, Blomström-Lundqvist C, Mazzanti A et al (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by: association for European paediatric and congenital cardiology (AEPC). Eur Heart J 36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316PubMedCrossRef

10.

Disertori M, Rigoni M, Pace N et al (2016) Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in Ischemic and nonischemic LV dysfunction: a meta-analysis. JACC Cardiovasc Imaging 9(9):1046–1055. https://doi.org/10.1016/j.jcmg.2016.01.033PubMedCrossRef

11.

Prystowsky EN, Nisam S (2000) Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter unsustained tachycardia trial. Multicenter automatic defibrillator implantation trial. Am J Cardiol 86(11):1214–1215. https://doi.org/10.1016/s0002-9149(00)01205-4PubMedCrossRef

12.

Bui AH, Cannon CP, Steg PG et al (2016) Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the platelet inhibition and patient outcomes (PLATO) trial. Circ Arrhythm Electrophysiol 9(2):e2951. https://doi.org/10.1161/CIRCEP.115.002951PubMedCrossRef

13.

Dagres N, Hindricks G (2013) Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J 34(26):1964–1971. https://doi.org/10.1093/eurheartj/eht109PubMedCrossRef

14.

Sabbag A, Suleiman M, Laish-Farkash A et al (2015) Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: from the Israeli ICD registry. Heart Rhythm 12(12):2426–2433. https://doi.org/10.1016/j.hrthm.2015.08.020PubMedCrossRef

15.

Moss AJ, Schuger C, Beck CA et al (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367(24):2275–2283. https://doi.org/10.1056/NEJMoa1211107PubMedCrossRef

16.

Willems D, Bak M, Tan H et al (2021) Ethical issues in two parallel trials of personalised criteria for implantation of implantable cardioverter defibrillators for primary prevention: the PROFID project‑a position paper. Open Heart 8(2):e1686. https://doi.org/10.1136/openhrt-2021-001686PubMedPubMedCentralCrossRef

17.

Goldberger JJ, Subacius H, Patel T et al (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63(18):1879–1889. https://doi.org/10.1016/j.jacc.2013.12.021PubMedCrossRef

18.

Di Marco A, Anguera I, Schmitt M et al (2017) Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 5(1):28–38. https://doi.org/10.1016/j.jchf.2016.09.017PubMedCrossRef

19.

Kuruvilla S, Adenaw N, Katwal AB et al (2014) Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 7(2):250–258. https://doi.org/10.1161/CIRCIMAGING.113.001144PubMedCrossRef

20.

Marume K, Noguchi T, Tateishi E et al (2018) Mortality and sudden cardiac death risk stratification using the noninvasive combination of wide QRS duration and late gadolinium enhancement in idiopathic dilated cardiomyopathy. Circ Arrhythm Electrophysiol 11(4):e6233. https://doi.org/10.1161/CIRCEP.117.006233PubMedCrossRef

21.

Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, Takahashi S (2008) MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 191(3):862–869. https://doi.org/10.2214/ajr.07.3089PubMedCrossRef

22.

Tung R, Bauer B, Schelbert H, Lynch JP 3rd, Auerbach M, Gupta P, Schiepers C, Chan S, Ferris J, Barrio M, Ajijola O, Bradfield J, Shivkumar K (2015) Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm 12(12):2488–2498. https://doi.org/10.1016/j.hrthm.2015.08.014PubMedPubMedCentralCrossRef

23.

Naruse Y, Sekiguchi Y, Nogami A et al (2014) Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 7(3):407–413. https://doi.org/10.1161/circep.113.000734PubMedCrossRef

24.

Hernandez-Madrid A, Paul T, Abrams D et al (2018) Arrhythmias in congenital heart disease: a position paper of the European heart rhythm association (EHRA), association for European paediatric and congenital cardiology (AEPC), and the European society of cardiology (ESC) working group on grown-up congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace 20(11):1719–1753. https://doi.org/10.1093/europace/eux380PubMedCrossRef

25.

Van Hare GF, Javitz H, Carmelli D et al (2004) Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 15(7):759–770. https://doi.org/10.1046/j.1540-8167.2004.03645.xPubMedCrossRef

26.

Khairy P, Van Hare GF, Balaji S et al (2014) PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the pediatric and congenital electrophysiology society (PACES) and the heart rhythm society (HRS). Endorsed by the governing bodies of PACES, HRS, the American college of cardiology (ACC), the American heart association (AHA), the European heart rhythm association (EHRA), the Canadian heart rhythm society (CHRS), and the international society for adult congenital heart disease (ISACHD). Can J Cardiol 30(10):e1–e63. https://doi.org/10.1016/j.cjca.2014.09.002PubMedCrossRef

27.

Harrison DA, Harris L, Siu SC et al (1997) Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol 30(5):1368–1373PubMedCrossRef

28.

Knauth AL, Gauvreau K, Powell AJ et al (2008) Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart 94(2):211–216. https://doi.org/10.1136/hrt.2006.104745PubMedCrossRef

29.

Khairy P, Landzberg MJ, Gatzoulis MA et al (2004) Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 109(16):1994–2000. https://doi.org/10.1161/01.cir.0000126495.11040.bdPubMedCrossRef

30.

Vehmeijer JT, Koyak Z, Bokma JP et al (2018) Sudden cardiac death in adults with congenital heart disease: does QRS-complex fragmentation discriminate in structurally abnormal hearts? Europace 20(FI1):f122–f128. https://doi.org/10.1093/europace/eux044PubMedCrossRef

31.

Priori SG, Wilde AA, Horie M et al (2013) HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in may 2013 and by ACCF, AHA, PACES, and AEPC in june 2013. Heart Rhythm 10(12):1932–1963. https://doi.org/10.1016/j.hrthm.2013.05.014PubMedCrossRef

32.

Anastasakis A, Papatheodorou E, Ritsatos K et al (2018) Sudden unexplained death in the young: epidemiology, aetiology and value of the clinically guided genetic screening. Europace 20(3):472–480. https://doi.org/10.1093/europace/euw362PubMedCrossRef

33.

Adler A, Rosso R, Chorin E et al (2016) Risk stratification in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm 13(1):299–310. https://doi.org/10.1016/j.hrthm.2015.08.038PubMedCrossRef

34.

Sieira J, Conte G, Ciconte G et al (2017) A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J 38(22):1756–1763. https://doi.org/10.1093/eurheartj/ehx119PubMedCrossRef

35.

Schwartz PJ, Ackerman MJ (2013) The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 34(40):3109–3116. https://doi.org/10.1093/eurheartj/eht089PubMedCrossRef

36.

Hayashi M, Denjoy I, Extramiana F et al (2009) Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119(18):2426–2434. https://doi.org/10.1161/circulationaha.108.829267PubMedCrossRef

37.

O’Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010–2020. https://doi.org/10.1093/eurheartj/eht439PubMedCrossRef

38.

Priori SG, Wilde AA, Horie M et al (2013) Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 15(10):1389–1406. https://doi.org/10.1093/europace/eut272PubMedCrossRef

39.

van Rijsingen IA, Arbustini E, Elliott PM et al (2012) Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 59(5):493–500. https://doi.org/10.1016/j.jacc.2011.08.078PubMedCrossRef

40.

van Rijsingen IA, van der Zwaag PA, Groeneweg JA et al (2014) Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 7(4):455–465. https://doi.org/10.1161/circgenetics.113.000374PubMedCrossRef

41.

Priori SG, Wilde AA, Horie M et al (2013) Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. https://doi.org/10.1093/europace/eut272PubMedCrossRef

42.

Pinto YM, Elliott PM, Arbustini E et al (2016) Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37(23):1850–1858. https://doi.org/10.1093/eurheartj/ehv727PubMedCrossRef

43.

Sawant AC, Te Riele AS, Tichnell C et al (2016) Safety of American heart association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm 13(1):199–207. https://doi.org/10.1016/j.hrthm.2015.08.035PubMedCrossRef

44.

Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC). Eur Heart J 42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484PubMedCrossRef

45.

Connolly SJ, Hallstrom AP, Cappato R et al (2000) meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J 21(24):2071–2078. https://doi.org/10.1053/euhj.2000.2476PubMedCrossRef

46.

Cronin EM, Bogun FM, Maury P et al (2020) 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 17(1):e2–e154. https://doi.org/10.1016/j.hrthm.2019.03.002PubMedCrossRef

47.

Pannone L, D’Angelo G, Gulletta S et al (2021) Amiodarone in ventricular arrhythmias: still a valuable resource? Rev Cardiovasc Med 22(4):1383–1392. https://doi.org/10.31083/j.rcm2204143PubMedCrossRef

Titel: Prävention des plötzlichen Herztods
verfasst von: Alireza Sepehri Shamloo, MD
Patrick Dilk
Nikolaos Dagres
Publikationsdatum: 11.03.2022
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2022
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-022-05106-w

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Erratum zu: Diagnose und Behandlung der kardialen Amyloidose

Erratum zu: Diagnostik und Therapie der Lungenembolie

Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension

2 Jahre COVID-19-Pandemie – was haben wir gelernt?